Last reviewed · How we verify

NCT04809025: EBPS

Comparation of Endoscopic Biopsy and Postoperative Specimen for the Molecular Diagnosis of Gastric Cancer

Recruiting now Last updated 29 September 2025
What this trial tests

trial testing endoscopy in Stomach Neoplasms in 510 participants. Currently enrolling.

Timeline
24 May 2021
Primary endpoint
1 September 2026
1 September 2026

Quick facts

Lead sponsorFudan University
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment510
Start date24 May 2021
Primary completion1 September 2026
Estimated completion1 September 2026
Sites1 location across China

Drugs / interventions tested

Conditions studied

Sponsor

Fudan University

Who can join

Adults 18 to 75, any sex, with Stomach Neoplasms or Endoscopy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to test the hypothesis that the diagnosis for histological type, histological grade, LAUREN type, HER-2 expression, MSI/dMMR status, and EBV status in gastric cancer is at least as reliable when performed on endoscopic biopsy specimens as on surgical resection specimens.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of endoscopy

Trials testing the same drug.

Other recruiting trials for Stomach Neoplasms

Currently open trials in the same condition.

Other Fudan University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04809025.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing